Galcanezumab is a medicine that helps prevent migraines and treats cluster headaches in adults. It is a shot you give yourself under the skin, usually once a month. It works by blocking a protein called CGRP that plays a part in causing these headaches.
Every report comes from a Lived member, sent anonymously.
Have you tried Emgality (Galcanezumab) for Migraines?
Galcanezumab, sold as Emgality, is a prescription injection for adults with two headache disorders. Its main use is preventing migraine: taken once a month, it aims to reduce how many migraine days a person has, rather than stopping an attack that has already started. People still need a separate plan for treating the attacks that do occur. Emgality is also approved for episodic cluster headache, a condition in which very severe, one-sided headaches around the eye come in bouts lasting weeks or months, separated by headache-free periods. In that case it is used during a cluster period to reduce how often attacks happen. The approval covers the episodic form only, not chronic cluster headache. The American Headache Society considers galcanezumab and related medicines a first-line choice for migraine prevention, meaning people do not have to try older preventive medicines first.
CGRP (calcitonin gene-related peptide) is a signaling molecule released by nerves, including nerves around the head and brain. Research over many years has shown that it plays a key role in how migraine attacks start and cause pain, which is why medicines that target it were developed specifically for migraine. Galcanezumab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. It binds CGRP itself and keeps it from reaching its receptor, so less of the signal gets through. Because the antibody stays in the body for weeks (about half is cleared in 27 days), one injection keeps working for a month. Blocking CGRP does not prevent every attack, and how much it helps varies from person to person.
Emgality comes as a single-dose prefilled pen or prefilled syringe that people inject under the skin of the belly, thigh, back of the upper arm or buttock. After training, most people give it to themselves at home. For migraine, treatment starts with a loading dose of two injections on the first day, which brings the medicine to its working level right away. After that, it is one injection once a month. A higher monthly dose was tested and did not work better. For episodic cluster headache, the dose is larger: three injections at the start of a cluster period, then three again each month until the period ends. The pens are kept in the refrigerator. Let one sit at room temperature for about 30 minutes before injecting, and do not warm it in hot water or a microwave or shake it. Do not use a dose that looks cloudy or has particles. A pen can stay out of the refrigerator for up to 7 days, but should not go back in afterward. If a dose is missed, take it as soon as possible and count the next month from that date.
Reactions where the shot was given, such as pain, redness or itching, are the most common side effect. In the migraine trials they affected 18% of people on Emgality compared with 13% on placebo, and they usually settle on their own. Constipation can occur and, rarely, becomes severe enough to need hospital care or surgery, most often after the first dose. Contact your prescriber if constipation is severe or does not ease. Allergic reactions such as rash or hives can happen, sometimes days after an injection, and can last a while. Call 911 for trouble breathing or swelling of the face, lips, tongue or throat, which can signal a serious allergic reaction called anaphylaxis.
People who have had a serious allergic reaction to galcanezumab or any ingredient in the injection should not use it. Blood pressure can rise, or existing high blood pressure can get worse, after starting CGRP-blocking medicines like Emgality. This was reported most often in the first week. People with high blood pressure or its risk factors may want to check readings early on and tell their prescriber if they climb. Emgality can also trigger or worsen Raynaud's phenomenon, in which fingers or toes become cold and numb and may turn white or blue, usually in response to cold or stress. If this happens, stop the medicine and contact your prescriber. People who already have Raynaud's should discuss this before starting. Galcanezumab is not broken down by the liver enzymes involved in most drug interactions, so major interactions are unlikely. Medicines that slow the digestive tract may make severe constipation more likely, so mention them to the prescriber. There is not enough information on its use in pregnancy or breastfeeding, and because it stays in the body for weeks to months after the last dose, anyone pregnant or planning pregnancy should talk it through with their prescriber. It has not been studied enough in children or teenagers.
In the main trials of people with episodic migraine, who started with about 9 migraine days a month, those on Emgality had about 4 to 5 fewer migraine days a month on average, compared with 2 to 3 fewer on placebo. About 6 in 10 cut their migraine days at least in half, against about 4 in 10 on placebo. In chronic migraine, where people started with about 19 migraine days a month, the average drop was about 5 days compared with about 3 on placebo, and 28% cut their migraine days in half versus 15% on placebo. Some people improve a lot, some modestly and some not at all. Because the benefit builds and varies, results are usually judged over a few monthly doses, much as the trials measured them over three to six months. Tracking headache days and how often acute medicine is used makes that judgment easier. If it helps, the prescriber and patient decide together how long to continue and when to review it. For episodic cluster headache, the evidence is thinner. In one trial of 106 adults, weekly attacks fell by about 9 on Emgality compared with about 5 on placebo over the first three weeks. Treatment usually stops when the cluster period ends.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Emgality (Galcanezumab), what you've noticed, or ask the community a question.